Neurofeedback Training for High Risk Psychosis

Sponsor
Hartford Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT03447548
Collaborator
National Institute of Mental Health (NIMH) (NIH)
105
2
2
34.1
52.5
1.5

Study Details

Study Description

Brief Summary

Young people who are at great risk for developing psychosis have cognitive deficits which are strongly related to functioning in the community. This study looks to target a specific cognitive skill called processing speed to see if improving the ability to process information in a timely manner will improve social function in adolescents and young adults at risk for developing schizophrenia. Half will receive neurofeedback cognitive training targeting processing speed while the other half will receive an active control.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Neurofeedback processing speed training
  • Behavioral: Active control
N/A

Detailed Description

Processing speed deficits are characteristic of schizophrenia and related to its functional impairment, including in its nascent stages, during a putatively prodromal or clinical high risk period. These cognitive deficits have proven relatively refractory to pharmacologic strategies, though the deficits can be improved with cognitive remediation programs in schizophrenia. The cognitive gains can then generalize to functional improvement, particularly early in the course of illness (i.e. first episode psychosis). Although processing speed deficits are also prevalent in young people identified as at clinical high risk for psychosis (i.e. "psychosis risk syndrome"), and related to their concurrent impaired function and predictive of later psychosis (onset of which occurs in 20-25% of clinical high risk cohorts), little research has focused on how to remediate these deficits in clinical high risk patients. Remediating core cognitive deficits in clinical high risk patients could plausibly address present functional impairment in these young people and moderate illness progression. The investigators propose to conduct a double-blind randomized trial in 105 clinical high risk patients to examine a focal processing speed training program versus an active control in terms of improvement in processing speed and social function, and reduction in prodromal symptom severity.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
105 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized controlled trial with intervention versus active controlRandomized controlled trial with intervention versus active control
Masking:
Double (Participant, Outcomes Assessor)
Masking Description:
Double blind
Primary Purpose:
Treatment
Official Title:
Neurofeedback Processing Speed Training to Improve Social Functioning in Teenagers and Young Adults at Clinical High Risk for Psychosis
Actual Study Start Date :
Mar 1, 2018
Anticipated Primary Completion Date :
Dec 1, 2020
Anticipated Study Completion Date :
Jan 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Processing speed training

Neurofeedback processing speed training

Behavioral: Neurofeedback processing speed training
Processing speed training on tablets that incorporates changes in pupil size to titrate the learning algorithm

Active Comparator: Active control

Computer games

Behavioral: Active control
Commercially available games on tablet

Outcome Measures

Primary Outcome Measures

  1. Change on the Wechsler Intelligence Scale Processing Speed Index [Baseline, 1 month, 2 month, 6 month]

    Change on a paper and pencil test of processing speed

Eligibility Criteria

Criteria

Ages Eligible for Study:
12 Years to 25 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Case identification and ascertainment depends on the fulfillment of the Criteria of
Prodromal States as evaluated using the Structured Interview for Prodromal Syndromes:

(1) attenuated positive symptom state which includes the emergence or worsening over the past year of non-psychotic disturbances in thought content, thought process or perceptual abnormality, (2) brief intermittent positive symptoms, and (3) genetic risk and deterioration.

  • Processing speed at least 0.5 Standard Deviation below the norm, as indexed by baseline performance on Digit Symbol Coding of 8 or below

  • Age range 12-25 (this age range also comprises the main period of risk for psychosis)

  • Written informed consent by patients >18 years old, and written assent by subjects <18 years old, with written informed consent by both parents (unless one is deceased or unavailable). Participants who turn 18 while in the study will be re-consented as adults through written informed consent.

Exclusion Criteria:
  • Current or past diagnosis of psychotic disorder noted at baseline assessment (schizophrenia, schizophreniform, bipolar, schizoaffective, major depression with psychotic features, substance-induced psychosis, psychosis due to a medical condition.

  • Neurological, neuroendocrine or major medical disorders: as putative prodromal symptoms could be secondary to these and unrelated to risk for primary psychotic disorders (clinical interview), including seizure disorder and history of significant traumatic brain injury

  • Intelligence Quotient < 70: as putative prodromal symptoms could be secondary to these and unrelated to risk for primary psychotic disorders

  • Positive symptoms that occur only in the context of substance abuse or withdrawal (i.e. within one month), so as not to include those at risk for substance-induced psychotic disorder

  • Lack of fluency in English: subjects must speak English to complete behavioral assessments for which psychometric properties have been established in English, complete cognitive training, and in order to comprehend and comply with protocol requirements.

  • Substance abuse or dependence (including alcohol and marijuana) in previous six months: for purposes of standardization and interpretation of cognitive data.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Connecting Adolescents with Psychosis (CAP), Child & Adolescents Day Program Hartford Connecticut United States 06106
2 Olin Neuropsychiatry Research Center Hartford Connecticut United States 06106

Sponsors and Collaborators

  • Hartford Hospital
  • National Institute of Mental Health (NIMH)

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hartford Hospital
ClinicalTrials.gov Identifier:
NCT03447548
Other Study ID Numbers:
  • HHC-2017-0190
  • 1R33MH111850-01A1
First Posted:
Feb 27, 2018
Last Update Posted:
Oct 29, 2019
Last Verified:
Oct 1, 2019
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Hartford Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 29, 2019